Fabien
Stauffert
a,
Jenny
Serra-Vinardell
b,
Marta
Gómez-Grau
b,
Helen
Michelakakis
c,
Irene
Mavridou
c,
Daniel
Grinberg
b,
Lluïsa
Vilageliu
b,
Josefina
Casas
d,
Anne
Bodlenner
*a,
Antonio
Delgado
*de and
Philippe
Compain
*a
aLaboratoire de Synthèse Organique et Molécules Bioactives (SYBIO), Université de Strasbourg/CNRS (UMR 7509), Ecole Européenne de Chimie, Polymères et Matériaux (ECPM), 25 rue Becquerel, 67087 Strasbourg, France. E-mail: philippe.compain@unistra.fr; annebod@unistra.fr
bDepartament de Genètica, Microbiologia i Estadística, Universitat de Barcelona (UB), IBUB, IRSJD, CIBER de Enfermedades Raras (CIBERER), Av. Diagonal 645, E-08028, Barcelona, Spain
cDepartment of Enzymology and Cellular Function, Institute of Child Health, Athens, 11527, Greece
dResearch Unit on BioActive Molecules (RUBAM), Departament de Química Biomèdica, Institut de Química Avançada de Catalunya (IQAC-CSIC), Jordi Girona 18, 08034 Barcelona, Spain. E-mail: delgado@rubam.net
eUnit of Pharmaceutical Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy, University of Barcelona (UB), Avga. Joan XXIII s/n, E-08028 Barcelona, Spain
First published on 14th September 2017
Correction for ‘Stereodivergent synthesis of right- and left-handed iminoxylitol heterodimers and monomers. Study of their impact on β-glucocerebrosidase activity’ by Fabien Stauffert et al., Org. Biomol. Chem., 2017, 15, 3681–3705.
In addition, since examples of divalent inhibitors based on enantiomeric iminosugar heads have been previously reported,1 the word ‘unprecedented’ should be deleted from the contents entry. The correct entry should read: “Janus-faced iminosugars act as pharmacological chaperones for the treatment of Gaucher disease.”
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
This journal is © The Royal Society of Chemistry 2017 |